Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor H and factor H-related protein 1 to pentraxin 3

Journal of Immunology

Volumn 189, Issue 4, 2012, Pages 1858-1867

  Kopp, Anne ^a   Strobel, Stefanie ^a   Tortajada, Agustín ^b,c   De Córdoba, Santiago Rodríguez ^b,c   Sánchez Corral, Pilar ^c,d   Prohászka, Zoltán ^e   López Trascasa, Margarita ^c,d   Józsi, Mihály ^a  

^a HANS KNÖLL INSTITUTE   (Germany)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BINDING PROTEIN; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H LIKE PROTEIN 1; COMPLEMENT FACTOR H RELATED PROTEIN 1; PENTRAXIN 3; PROTEIN VARIANT; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY ISOLATION; ARTICLE; BINDING SITE; CELL ACTIVATION; CELL PH; CONCENTRATION RESPONSE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

AUTOANTIBODIES; AUTOANTIGENS; C-REACTIVE PROTEIN; COMPLEMENT C3B INACTIVATOR PROTEINS; COMPLEMENT FACTOR H; EXTRACELLULAR MATRIX; HEMOLYTIC-UREMIC SYNDROME; HUMANS; SERUM AMYLOID P-COMPONENT;

EID: 84864823657     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200357     Document Type: Article

References (55)

1. Mantovani, A., C. Garlanda, A. Doni, and B. Bottazzi. 2008. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J. Clin. Immunol. 28: 1-13.
2. Yamasaki, K., M. Kurimura, T. Kasai, M. Sagara, T. Kodama, and K. Inoue. 2009. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin. Chem. Lab. Med. 47: 471-477.
3. Bottazzi, B., A. Doni, C. Garlanda, and A. Mantovani. 2010. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 28: 157-183.
4. Lee, T. H., G. W. Lee, E. B. Ziff, and J. Vilcek. 1990. Isolation and characterization of eight tumor necrosis factor-induced gene sequences from human fibroblasts. Mol. Cell. Biol. 10: 1982-1988.
5. Breviario, F., E. M. d'Aniello, J. Golay, G. Peri, B. Bottazzi, A. Bairoch, S. Saccone, R. Marzella, V. Predazzi, M. Rocchi, et al. 1992. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J. Biol. Chem. 267: 22190-22197.
6. Norata, G. D., C. Garlanda, and A. L. Catapano. 2010. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc. Med. 20: 35-40.
7. Luchetti, M. M., G. Piccinini, A. Mantovani, G. Peri, C. Matteucci, G. Pomponio, M. Fratini, P. Fraticelli, P. Sambo, C. Di Loreto, et al. 2000. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin. Exp. Immunol. 119: 196-202. (Pubitemid 30064610)
8. Tong, M., J. J. Carrero, A. R. Qureshi, B. Anderstam, O. Heimbürger, P. Bárány, J. Axelsson, A. Alvestrand, P. Stenvinkel, B. Lindholm, and M. E. Suliman. 2007. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin. J. Am. Soc. Nephrol. 2: 889-897.
9. Moalli, F., S. Jaillon, A. Inforzato, M. Sironi, B. Bottazzi, A. Mantovani, and C. Garlanda. 2011. Pathogen recognition by the long pentraxin PTX3. J. Biomed. Biotechnol. 2011: 830421.
10. Scarchilli, L., A. Camaioni, B. Bottazzi, V. Negri, A. Doni, L. Deban, A. Bastone, G. Salvatori, A. Mantovani, G. Siracusa, and A. Salustri. 2007. PTX3 interacts with inter-alpha-trypsin inhibitor: implications for hyaluronan organization and cumulus oophorus expansion. J. Biol. Chem. 282: 30161-30170. (Pubitemid 350035268)
11. Rovere, P., G. Peri, F. Fazzini, B. Bottazzi, A. Doni, A. Bondanza, V. S. Zimmermann, C. Garlanda, U. Fascio, M. G. Sabbadini, et al. 2000. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 96: 4300-4306.
12. Bottazzi, B., V. Vouret-Craviari, A. Bastone, L. De Gioia, C. Matteucci, G. Peri, F. Spreafico, M. Pausa, C. D'Ettorre, E. Gianazza, et al. 1997. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J. Biol. Chem. 272: 32817-32823. (Pubitemid 28023616)
13. Ma, Y. J., A. Doni, T. Hummelshøj, C. Honoré, A. Bastone, A. Mantovani, N. M. Thielens, and P. Garred. 2009. Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition. J. Biol. Chem. 284: 28263-28275.
14. Ma, Y. J., A. Doni, M. O. Skjoedt, C. Honoré, M. Arendrup, A. Mantovani, and P. Garred. 2011. Heterocomplexes of mannose-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system. J. Biol. Chem. 286: 3405-3417.
15. Gout, E., C. Moriscot, A. Doni, C. Dumestre-Pérard, M. Lacroix, J. Pérard, G. Schoehn, A. Mantovani, G. J. Arlaud, and N. M. Thielens. 2011. M-ficolin interacts with the long pentraxin PTX3: a novel case of cross-talk between soluble pattern-recognition molecules. J. Immunol. 186: 5815-5822.
16. Deban, L., H. Jarva, M. J. Lehtinen, B. Bottazzi, A. Bastone, A. Doni, T. S. Jokiranta, A. Mantovani, and S. Meri. 2008. Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J. Immunol. 181: 8433-8440.
17. Braunschweig, A., and M. Józsi. 2011. Human pentraxin 3 binds to the complement regulator c4b-binding protein. PLoS ONE 6: e23991.
18. Ferreira, V. P., M. K. Pangburn, and C. Cortés. 2010. Complement control protein factor H: the good, the bad, and the inadequate. Mol. Immunol. 47: 2187-2197.
19. Józsi, M., T. Manuelian, S. Heinen, M. Oppermann, and P. F. Zipfel. 2004. Attachment of the soluble complement regulator factor H to cell and tissue surfaces: relevance for pathology. Histol. Histopathol. 19: 251-258. (Pubitemid 38120210)
20. Pangburn, M. K. 2002. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J. Immunol. 169: 4702-4706. (Pubitemid 35217129)
21. Józsi, M., M. Oppermann, J. D. Lambris, and P. F. Zipfel. 2007. The C-terminus of complement factor H is essential for host cell protection. Mol. Immunol. 44: 2697-2706. (Pubitemid 46240314)
22. Wu, J., Y. Q. Wu, D. Ricklin, B. J. Janssen, J. D. Lambris, and P. Gros. 2009. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 10: 728-733.
23. Zipfel, P. F., and C. Skerka. 1999. FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function. Immunol. Today 20: 135-140. (Pubitemid 29130343)
24. de Córdoba, S. R., and E. G. de Jorge. 2008. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin. Exp. Immunol. 151: 1-13.
25. Józsi, M., and P. F. Zipfel. 2008. Factor H family proteins and human diseases. Trends Immunol. 29: 380-387.
26. Noris, M., and G. Remuzzi. 2009. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361: 1676-1687.
27. Dragon-Durey, M. A., C. Loirat, S. Cloarec, M. A. Macher, J. Blouin, H. Nivet, L. Weiss, W. H. Fridman, and V. Frémeaux-Bacchi. 2005. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16: 555-563. (Pubitemid 41725154)
28. Józsi, M., C. Licht, S. Strobel, S. L. Zipfel, H. Richter, S. Heinen, P. F. Zipfel, and C. Skerka. 2008. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111: 1512-1514. (Pubitemid 351213440)
29. Józsi, M., S. Strobel, H. M. Dahse, W. S. Liu, P. F. Hoyer, M. Oppermann, C. Skerka, and P. F. Zipfel. 2007. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 110: 1516-1518. (Pubitemid 47443967)
30. Ferreira, V. P., A. P. Herbert, C. Cortés, K. A. McKee, B. S. Blaum, S. T. Esswein, D. Uhrín, P. N. Barlow, M. K. Pangburn, and D. Kavanagh. 2009. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J. Immunol. 182: 7009-7018.
31. Lehtinen, M. J., A. L. Rops, D. E. Isenman, J. van der Vlag, and T. S. Jokiranta. 2009. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J. Biol. Chem. 284: 15650-15658.
32. Venables, J. P., L. Strain, D. Routledge, D. Bourn, H. M. Powell, P. Warwicker, M. L. Diaz-Torres, A. Sampson, P. Mead, M. Webb, et al. 2006. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med. 3: e431.
33. Zipfel, P. F., M. Edey, S. Heinen, M. Józsi, H. Richter, J. Misselwitz, B. Hoppe, D. Routledge, L. Strain, A. E. Hughes, et al. 2007. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 3: e41.
34. Abarrategui-Garrido, C., R. Martínez-Barricarte, M. López-Trascasa, S. R. de Córdoba, and P. Sánchez-Corral. 2009. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 114: 4261-4271.
35. Moore, I., L. Strain, I. Pappworth, D. Kavanagh, P. N. Barlow, A. P. Herbert, C. Q. Schmidt, S. J. Staniforth, L. V. Holmes, R. Ward, et al. 2010. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115: 379-387.
36. Dragon-Durey, M. A., C. Blanc, F. Marliot, C. Loirat, J. Blouin, C. Sautes- Fridman, W. H. Fridman, and V. Frémeaux-Bacchi. 2009. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J. Med. Genet. 46: 447-450.
37. Heinen, S., A. Hartmann, N. Lauer, U. Wiehl, H. M. Dahse, S. Schirmer, K. Gropp, T. Enghardt, R. Wallich, S. Hälbich, et al. 2009. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 114: 2439-2447.
38. Kühn, S., and P. F. Zipfel. 1995. The baculovirus expression vector pBSV-8His directs secretion of histidine-tagged proteins. Gene 162: 225-229.
39. Hindmarsh, E. J., and R. M. Marks. 1998. Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. J. Immunol. 160: 6128-6136. (Pubitemid 28298077)
40. Jokiranta, T. S., V. P. Jaakola, M. J. Lehtinen, M. Pärepalo, S. Meri, and A. Goldman. 2006. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J. 25: 1784-1794.
41. Lardner, A. 2001. The effects of extracellular pH on immune function. J. Leukoc. Biol. 69: 522-530. (Pubitemid 32294836)
42. Hammond, D. J., Jr., S. K. Singh, J. A. Thompson, B. W. Beeler, A. E. Rusiñol, M. K. Pangburn, L. A. Potempa, and A. Agrawal. 2010. Identification of acidic pH-dependent ligands of pentameric C-reactive protein. J. Biol. Chem. 285: 36235-36244.
43. Sjöberg, A. P., G. A. Manderson, M. Mörgelin, A. J. Day, D. Heinegård, and A. M. Blom. 2009. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol. Immunol. 46: 830-839.
44. Oppermann, M., T. Manuelian, M. Józsi, E. Brandt, T. S. Jokiranta, S. Heinen, S. Meri, C. Skerka, O. Götze, and P. F. Zipfel. 2006. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin. Exp. Immunol. 144: 342-352.
45. Strobel, S., C. Abarrategui-Garrido, E. Fariza-Requejo, H. Seeberger, P. Sánchez-Corral, and M. Józsi. 2011. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. Kidney Int. 80: 397-404.
46. Daigo, K., N. Yamaguchi, T. Kawamura, K. Matsubara, S. Jiang, R. Ohashi, Y. Sudou, T. Kodama, M. Naito, K. Inoue, and T. Hamakubo. 2012. The proteomic profile of circulating pentraxin 3 (PTX3) complex in sepsis demonstrates the interaction with azurocidin 1 and other components of neutrophil extracellular traps. Mol. Cell. Proteomics 11: M111.015073. 10.1074/mcp.M111.015073.
47. Sjöberg, A. P., L. A. Trouw, and A. M. Blom. 2009. Complement activation and inhibition: a delicate balance. Trends Immunol. 30: 83-90.
48. Hindmarsh, E. J., and R. M. Marks. 1998. Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C. Eur. J. Immunol. 28: 1052-1062. (Pubitemid 28116219)
49. Clark, S. J., R. Perveen, S. Hakobyan, B. P. Morgan, R. B. Sim, P. N. Bishop, and A. J. Day. 2010. Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. J. Biol. Chem. 285: 30192-30202.
50. Didangelos, A., X. Yin, K. Mandal, M. Baumert, M. Jahangiri, and M. Mayr. 2010. Proteomics characterization of extracellular space components in the human aorta. Mol. Cell. Proteomics 9: 2048-2062.
51. Deban, L., R. C. Russo, M. Sironi, F. Moalli, M. Scanziani, V. Zambelli, I. Cuccovillo, A. Bastone, M. Gobbi, S. Valentino, et al. 2010. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat. Immunol. 11: 328-334.
52. Jaillon, S., G. Peri, Y. Delneste, I. Frémaux, A. Doni, F. Moalli, C. Garlanda, L. Romani, H. Gascan, S. Bellocchio, et al. 2007. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J. Exp. Med. 204: 793-804. (Pubitemid 46631609)
53. Roumenina, L. T., M. M. Ruseva, A. Zlatarova, R. Ghai, M. Kolev, N. Olova, M. Gadjeva, A. Agrawal, B. Bottazzi, A. Mantovani, et al. 2006. Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry 45: 4093-4104.
54. Sánchez-Corral, P., C. González-Rubio, S. Rodríguez de Córdoba, and M. López-Trascasa. 2004. Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol. Immunol. 41: 81-84. (Pubitemid 38609399)
55. Strobel, S., P. F. Hoyer, C. J. Mache, E. Sulyok, W. S. Liu, H. Richter, M. Oppermann, P. F. Zipfel, and M. Józsi. 2010. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol. Dial. Transplant. 25: 136-144.